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doi:10.1016/j.jtcvs.2008.02.037Objective: The development of the Amplatzer Membranous VSD Occluder (AGA
Medical Corp, Plymouth, Minn) for closure of the perimembranous ventricular septal
defect has ameliorated many of the technical difficulties of previous devices. Appli-
cation of this new technology requires comparative evaluation with the current stan-
dard of surgical repair. We report our experience of complete heart block associated
with device closure of a large perimembranous ventricular septal defect with unequiv-
ocal indications for intervention.
Methods: We performed a retrospective review of 20 patients between January 2003
and August 2005 who underwent perimembranous ventricular septal defect device
closure, 18 with hemodynamically large shunts meeting the surgical criteria for inter-
vention. The median age was 1.6 years (range, 0.5–16.2 years), and the median weight
was 9.7 kg (range, 6.2–43 kg).
Results:Acute complete shunt occlusion was achieved in all patients. There were no
acute procedural complications. The median follow-up time was 23.1 months
(range, 1–37.8 months). Four (22%) had complete heart block at 17 days, 4.2
months, 8.8 months, and 37.5 months after implantation, respectively. No risk fac-
tors were identified for development of complete heart block, including age, weight,
trisomy 21, preceding conduction abnormalities, perimembranous ventricular septal
defect size related to body surface area or device size, and progressive device flat-
tening.
Conclusions: Device closure of large perimembranous ventricular septal defects
in infants and children with the Amplatzer Membranous VSD Occluder resulted in
excellent closure rates but an unacceptably high rate of complete heart block.
P
erimembranous ventricular septal defects (PMVSDs) in infants and young chil-
dren are the most common cause of a hemodynamically significant ventricular
septal defect (VSD). Although device closure of certain VSDs (muscular, re-
sidual postsurgical, posttraumatic, and postinfarction defects) is highly effective,
either by means of percutaneous catheterization or collaborative hybrid-type ap-
proaches,1-4 initial attempts at transcatheter PMVSDs were largely unsuccessful.5,6
The development of the Amplatzer Membranous VSD Occluder (AGA Medical
Corp, Plymouth, Minn) has led to numerous case series, and more than 2000 devices
have been implanted worldwide.7-13 Short- and medium-term follow-up indicates that
many of the shortcomings of previous devices have been overcome, especially with
respect to technical feasibility, shunt occlusion, and valvular dysfunction. However,
there has been considerable uncertainty about the clinical importance of some of the
occluded VSDs and also the long-term follow-up of these patients.10 This new tech-
nology requires comparison with the standard practice of surgical repair.
After this preliminary experience, our institution embarked on an evaluation of de-
vice closure of the PMVSD with unequivocal indications for intervention in patients
who would have otherwise undergone surgical closure. Reports of device-associated
complete heart block (CHB) have emerged.13-17The Journal of Thoracic and Cardiovascular Surgery c Volume 136, Number 5 1223
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DAbbreviations and Acronyms
CHB 5 complete heart block
PMVSD 5 perimembranous ventricular septal defect
PPM 5 permanent pacemaker
RBBB 5 right bundle branch block
VSD 5 ventricular septal defect
We report on our experience of CHB associated with
device closure of the hemodynamically significant PMVSD.
Materials and Methods
Review of the cardiac database identified all patients who underwent
PMVSD device closure with the Amplatzer Membranous VSD
Occluder. Clinical records, angiograms, electrocardiograms, and
echocardiograms were reviewed. The study was approved by the
Research Ethics Board at the Hospital for Sick Children.
Patient Population
Patients were eligible for device closure if 1 or more of the following
indications were present: pulmonary-to-systemic blood flow (Qp/
Qs) ratio of greater than 1.5, heart failure not controlled with med-
ications, evidence of left heart volume loading, and a history of pre-
vious endocarditis. Exclusion criteria included weight of less than 6
kg, inlet extension of the PMVSD, pulmonary vascular resistance
index of greater than 7 WU/m2 that was unresponsive to oxygen,
additional lesions requiring surgical intervention (right/left ventric-
ular outflow tract obstruction and aortic regurgitation), and parental
preference for surgical intervention. For the purpose of this report,
we focus on patients with either a large shunt (Qp/Qs ratio of $2
or with pulmonary hypertension in the presence of a Qp/Qs ratio
of ,2). Pulmonary hypertension was defined as a mean pulmonary
artery pressure of 20 mm Hg or greater based on the original natural
history studies.18
VSD Sizing and Device Implantation
PMVSD anatomy and initial sizing were determined by means of
transthoracic echocardiography. The parasternal short-axis and api-
cal 4-chamber views were used to measure the short- and long-axis
diameters, respectively, of the defect. Where the VSD was restric-
tive, size was based on the smallest jet width by means of color im-
aging. Baseline valvular regurgitation, aortic cusp prolapse, and the
pressure gradient across the VSD were assessed.
All PMVSDswere closed with the AmplatzerMembranous VSD
Occluder. Cardiac catheterization was performed after achievement
of general anesthesia. Right and left heart hemodynamic assess-
ments were performed. Device implantation followed the recom-
mended protocol.7,8,11 Briefly, the PMVSD was crossed with
a wire from the left ventricular side, the wire was snared in the pul-
monary artery and exteriorized to the femoral vein to form an arte-
riovenous circuit, and the device was implanted through a long
sheath traversing the PMVSD from the right to the left ventricle.
Transesophageal echocardiography was used to assist in assessment
of defect size and device position and to exclude device distortion of
surrounding cardiac structures. The device was generally selected to
be 1 to 2 mm larger than the VSD, as assessed by the combination of1224 The Journal of Thoracic and Cardiovascular Surgery c Noechocardiography and left ventricular angiography. Given that the
device is circular in shape and the PMVSDmore elliptical, the larger
of the short- and long-axis defect diameters was used. The Amplat-
zer Membranous VSD Occluder was available in 2-mm increments
at the time of this study.
Follow-up
All patients were monitored in the hospital for 24 hours after device
implantation, and chest radiography, electrocardiography, and echo-
cardiography were performed before discharge. Outpatient follow-
up was with an electrocardiogram and echocardiogram at 1 week,
1 month, 6 months, 1 year, and then yearly.
Follow-up echocardiograms were reviewed to assess residual
shunt and valvular regurgitation. We found attempts to measure
disk diameter by means of echocardiography unreliable and there-
fore documented our subjective impression of whether the device
had flattened over time.
Statistical Analysis
Descriptive statistics are reported as medians and ranges. The nu-
meric variables for the 18 patients with hemodynamically significant
PMVSDs were split into CHB and non-CHB groups and compared
with the Mann–Whitney test. The Fisher test was used to compare
categorical variables between the groups. All data analysis was per-
formed in R 2.5.1.19
Results
Between January 2003 and August 2005, 20 patients (12
male patients) underwent PMVSD device implantation. Pa-
tient demographics and clinical and hemodynamic data are
summarized in Table 1. The median age was 1.6 years (range,
0.5–16.2 years), and the median weight was 9.7 kg (range,
6.2–43 kg). Eighteen patients met unequivocal criteria for
VSD intervention (Qp/Qs ratio of $2 [n 5 10] or mean pul-
monary artery pressure of$20 mm Hg with a Qp/Qs ratio of
,2:1 [n5 8]). Patient 12 had left ventricular noncompaction
with restrictive cardiomyopathy and high pulmonary artery
pressures. Defects that did not meet the criteria of a large
shunt were in patient 19, who was referred for closure after
a documented episode of infective endocarditis, and patient
20, who was a 7-year-old who was asymptomatic, taking
no medication, and who had a cardiac nuclear angiogram
that was difficult to interpret and reported a Qp/Qs ratio of
between 1.5:1 and 3:1. Echocardiographic analysis demon-
strated a gradient of 103 mm Hg across the VSD, a left ven-
tricular end-diastolic dimension z score of 12.7, and a left
atrial diameter z score of 11.9. At catheterization, the Qp/
Qs ratio was 1.8:1, and the mean pulmonary artery pressure
was 15 mm Hg. There was a strong preference for closure
by the referring cardiologist and the parents.
During this time period, 25 patients weighing 6 kg or more
underwent surgical intervention with a PMVSD as the pri-
mary indication for the operation. Those with the secondary
diagnoses of atrial septal defect, patent ductus arteriosus, and
patent foramen ovale were included. Of this group, 13 (52%)vember 2008
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DTABLE 1. Patient characteristics and hemodynamic and procedural data
Patient
no. Age (y)
Weight
(kg)
Qp/Qs
ratio
VSD size
(mm)
VSD pressure
gradient (mm Hg)
PAPm
(mm Hg)
Device size
(mm)
Follow-up
(mo)
Trisomy
21 CHB
1 0.9 8.1 1.6 12 42 49 14 26.1 1 1
2 1.2 8.2 2.3 7 64 26 8 37.8 1 1
3 1.3 9.9 1.9 10 33 28 12 23.9 2 1
4 1.5 10.3 1.4 10 8 55 12 5.6 1 1
5 0.5 6.2 2.0 7 18 26 8 24.6 1 2
6 0.7 6.8 2.4 9 8 35 12 21.3 2 2
7 1.5 7.5 1.6 10 36 55 12 32.2 2 2
8 1.2 7.9 2.0 6 35 19 8 20.2 1 2
9 1.4 8.2 2.0 9 51 30 10 25.4 2 2
10 0.8 8.4 3.4 14 35 56 14 19.9 2 2
11 1.8 8.8 3.0 12 23 39 14 31.5 2 2
12 1.6 9.4 1.0 11 14 57 14 17.1 2 2
13 1.6 10.3 2.8 12 58 28 14 1 2 2
14 2.1 12.2 1.5 10 66 24 12 11.9 2 2
15 3.0 12.6 1.4 8 56 59 10 20.3 1 2
16 8.4 26.6 2.3 8 74 16 10 36.3 - 2
17 10.5 38.5 1.0 12 112 35 14 22.4 2 -
18 16.2 43.0 3.0 17 67 27 18 34.1 1 2
19* 5.4 19.1 1.0 6 77 17 6 15.9 2 2
20* 7.2 28.8 1.8 6 103 15 8 28.5 2 2
Median (range) 1.6 (0.5–16.2) 9.7 (6.2–43) 2.0 (1–3.4) 9.5 (6–17) 47 (8–112) 29 (15–59) 12 (6–18) 23.1 (1–37.8)
VSD, Ventricular septal defect; PAPm, mean pulmonary artery pressure; CHB, complete heart block. *Excluded in analysis of hemodynamically significant
perimembranous ventricular septal defects.weighed 8 kg or more, 12 (48%) weighed 10 kg or more, and
only 1 weighed 16 kg or more, reflecting our institutional cri-
teria for PMVSD intervention being predominantly in small
patients with large shunts. None of these patients have had
CHB.
A device was deployed successfully in the standard fash-
ion in all cases. Themedian fluoroscopic time was 27minutes
(range, 13–50 minutes). Acute complete VSD shunt occlu-
sion was achieved in all patients. There were no major proce-
dural complications. In 4 children (patients 7, 10, 11, and 12)
the initial device prolapsed through the defect and was re-
placed with the next size up (2 mm larger). In 2 children
the device size was 3 mm greater than the VSD size. In pa-
tient 12 the initial 12-mm device prolapsed through the 11-
mm VSD, and a 14-mm device was successfully implanted.
Patient 6 had a 9-mm VSD closed with a 12-mm device.
This device looked bulky after delivery but could not be re-
trieved because of entanglement within the tricuspid valve.
Initially, tricuspid valve regurgitation was moderate, but 13
months later, it was mild.
Follow-up time at the last clinical assessment or until heart
transplantation or development of CHB was a median of 23.1
months (range, 1–37.8months). One patient had only 1month
of follow-up (patient 13). There were no deaths or device em-
bolization. Twelve patients had new or increased valvular re-
gurgitation (60%), none of more than a mild degree at last
follow-up. One child had self-limiting hemolysis that did notThe Journal of Thorarequire blood transfusion (patient 1). The patient with restric-
tive cardiomyopathy had disease progression and underwent
successful transplantation 2.2 years after device implantation.
New conduction abnormalities were observed after de-
vice implantation in 16 (80%) children, 7 of whom had
pre-existing abnormalities. The new abnormalities were bi-
fascicular block (n 5 1), incomplete right bundle branch
block (RBBB; n 5 2), complete RBBB (n 5 3), and first-
degree heart block (n 5 1). These were transient in 3 and
permanent in 13 (65%) patients. Four (20%) patients had
CHB presenting at 17 days, 4.2 months, 8.8 months, and
37.5 months, respectively, after implantation.
Patient 4 presented with 3 syncopal episodes, 2 of which
were associated with seizures. High-grade second-degree
heart block and periods of asystole up to 30 seconds were ob-
served. Emergency treatment with an isoproterenol infusion
and transvenous pacing was initiated. The parents declined
a trial of corticosteroids, and the device was removed at the
time of permanent pacemaker (PPM) implantation and sinus
rhythm recovered 1 day later. In the other 3 patients, CHB
was diagnosed during routine follow-up. Ventricular rates
were 43, 49, and 50 beats/min. All patients had at least 1 Hol-
ter examination demonstrating continuous sinus rhythm
before development of CHB. All patients underwent PPM
implantation within 0 to 10 days of diagnosis. The device
was left in situ in 3 patients with late-onset CHB, and all
remain pacemaker dependent.cic and Cardiovascular Surgery c Volume 136, Number 5 1225
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DWe sought to identify risk factors for CHB using a de-
tailed review of the cases, including procedural details, echo-
cardiograms, and angiograms. There was no discernible
difference between the CHB and non-CHB groups (Table
2), irrespective of whether we examined only the 18 patients
who met the hemodynamic criteria for intervention or the
extended group of all 20 patients (data not shown). Electro-
cardiograms with or without Holter examination after im-
plantation and before diagnosis of CHB were normal for 2
patients and in 1 patient indicated new RBBB. Patient 1
with trisomy 21 had baseline PR-interval prolongation and
progressed to bifascicular block (24 hours), trifascicular
block (2 weeks), and then CHB (4.2 months). In the other
3 patients, there was no warning of CHB. Neither of the 2
patients with a device 3 mm larger than the VSD size had
CHB.
Immediately after implantation, the device disks did not
appear fully flattened in 14 (78%) patients and progressively
flattened in 7 (50%) patients. However, the 2 groups did not
differ significantly with respect to initial or subsequent device
shape (P 5 1.00 and P 5 .6, respectively).
Concern that use of the largest diameter of the VSD might
lead to device oversizing and CHB led the manufacturer
(AGA Medical Corp) to recommend a new formula (square
root of the product of the short- and long-axis diameters of
the PMVSD) for device sizing based on an assumed elliptical
shape. Retrospective application of this new formula in our
series recommended smaller devices in 10 (71%) of the pa-
tients without CHB and in 3 (75%) of the patients with
CHB. The ratio of the new device to the used device did
not differ between the 2 groups (Table 2). All 4 devices
that dislodged and required larger sizes were in the non-
CHB group. In 2 of the 4 instances of device dislodgement,
a device that was the same size or smaller than that recom-
TABLE 2. Comparison between non-CHB and CHB groups
(n 5 18)
Non-CHB
group (n 5 14)
CHB group
(n 5 4)
P
value
Age (y) 1.6 (0.5–16.2) 1.3 (0.9–1.5) .22
Weight (kg) 9.1 (6.2–43) 9.1 (8.1–10.3) .79
Qp/Qs ratio 2 (1.0–3.4) 1.8 (1.4–2.3) .45
Mean PAP (mm Hg) 33 (16–59) 39 (26–55) .91
VSD size (mm) 10 (6–17) 9.5 (7–12) .71
VSD/BSA 22.1 (8.2–27.5) 20.7 (16.3–28) .79
Device size (mm) 12 (8–18) 12 (8–14) .74
Device/VSD 1.2 (1.0–1.3) 1.2 (1.1–1.3) .87
''New device''/device 0.9 (0.7–1.1) 0.9 (0.8–1.0) .91
Trisomy 21 4 3 .24
Values are presented as medians (ranges). CHB, Complete heart block; PAP,
pulmonary artery pressure; VSD, ventricular septal defect; BSA, body
surface area; ''New device''/device, device size by the new formula to
used device ratio.1226 The Journal of Thoracic and Cardiovascular Surgery c Nmended by this new formula was actually initially implanted
but subsequently required a larger implant.
Discussion
The development of the Amplatzer Membranous VSD Oc-
cluder and similar devices has ameliorated many of the tech-
nical difficulties and decreased distortion of the surrounding
valve apparatus that occurred with previous devices. These
advantages have lead to renewed interest in this technique.
Initial experience from multiple institutions reported no mor-
tality, high acute technical success (89% to 100%), and high
occlusion rates (84% to 100%) in the absence of any major
concerns.7-13 Similar to others, we also achieved high techni-
cal success with 100% shunt occlusion and good acute
outcomes. Longer-term follow-up in our institution unveiled
a high frequency (22%) of CHB. Concurrently, sporadic
published reports of acute and late CHB emerged with a re-
ported incidence of 1% to 5%.14-17 Based on these data,
PMVSD device implantation was terminated at our institu-
tion. Most recently, Butera and colleagues13 report longer-
term follow-up in 104 patients at a median of 38.5 months.
The incidence of CHB was 8.7%, and PPM was required
in 6 (5.7%) patients, 2 in the early phase and 4 during late
follow-up.
Conduction system injury from mechanical trauma/com-
pression by the delivery system or device causing acute in-
traprocedural CHB has a reasonable probability of early
resolution. Chronic inflammation or fibrosis is more likely
to be responsible for the late-onset type.15,20 Clearly, some
cases of early CHB resolve spontaneously or with temporary
pacing, corticosteroid and/or high-dose acetylsalicylic acid
therapy, or device removal.10,16 Recovery of sinus rhythm
after PPM implantation without device removal has also
been reported.7,14 However, in early-onset CHB it is likely
that the highest chance of sinus rhythm recovery is with
device removal.13 Of most concern is the late onset, lack
of predictive factors, and potentially life-threatening presen-
tation of CHB. Hemodynamic instability, including syncope,
has been the presenting event in 10 reported cases, including
our patient with seizure. Others were discovered on routine
scheduled follow-up.13-17 CHB occurred as late as 37
months after device implantation in our series.
Identifying Risk Factors for Device-associated CHB
PMVSD anatomy. The simple anatomic classification of
a VSD in the perimembranous region belies the wide vari-
ability of its shape. The common denominator of such defects
is the fibrous continuity between the leaflets of the tricuspid
and aortic valves, which form part of the defect’s margins,
with the conduction tissue coursing posteroinferiorly.21
This begs the question of whether one device shape fits all
PMVSDs and more prudently whether such a device can
avoid damaging the conduction tissue.ovember 2008
Predescu et al Surgery for Congenital Heart Disease
CH
DBecause of concern that inlet extension of the VSD might
predispose to CHB, these patients were specifically excluded
in our series.16
Device sizing. VSD sizing is challenging because the
complexity of PMVSD geometry cannot be captured by mea-
suring 1 or 2 dimensions available by means of standard
echocardiographic and angiographic imaging. Echocardio-
graphic analysis can overestimate VSD diameter by 21%.22
Efforts to minimize possible oversizing include new recom-
mendations for device sizing, accounting for the elliptical
shape of the PMVSD. Retrospective application of this new
device size formula failed to identify oversizing as a risk fac-
tor. There are no reports of prospective application of this
new method of device size selection. Device oversizing
was not a risk factor for CHB in the series by Butera and
colleagues.13
Progressive device flattening of an originally oversized
device has been hypothesized as a mechanism for the devel-
opment of CHB. However, this was not observed in the
patients with CHB in other series14,15 and was not signifi-
cantly different in the patients with and without CHB in
our series.
Patient characteristics. It has been suggested that smaller
infants might be at higher risk, but in the reported cases of
CHB, age ranged from 2.5 to 12 years, and weights ranged
from 14 to 45 kg.13-16 Weight in our series was lower than
that of other series, with the median weight for the entire co-
hort being 9.7 kg, reflecting our criteria for VSD intervention.
There was no significant difference in weight between the
CHB and non-CHB groups. In fact, the smallest 2 patients,
weighing 6.2 and 6.8 kg, both with large shunts and pulmo-
nary hypertension, did not have CHB. The minimum weight
at which device implantation can be considered remains to be
determined.
PMVSD surgery. VSD management aims to avoid mor-
bidity and prevent premature mortality from chronic heart
failure and pulmonary hypertension.23,24 Excellent outcomes
are expected for the timely diagnosed PMVSD. Surgical in-
tervention for the isolated PMVSD in experienced centers
has achieved this with minimal mortality (0% at our institu-
tion since the year 2000, unpublished data) and a very low in-
cidence of CHB (0.7% to 1%).25,26 Tucker and associates26
report from the Pediatric Cardiac Care Consortium database
an incidence of PPM implantation in 0.8% of 1739 patients
who weighed more than 8 kg and were primarily operated
on to repair PMVSDs (ie, comparable patients eligible for
PMVSD device closure). In the contemporary era of 1315 pa-
tients, the PPM rate was 0.4%, and hospital mortality was
0.2%.26Morbidity remains with requirement of cardiopulmo-
nary bypass, sternotomy, and psychosocial effect and thus
provides impetus for the search for alternative therapies.27,28
Until there are data to demonstrate that the incidence of CHB
can be decreased by changes in patient selection or device
modification, the potential benefits of reducing surgical inter-The Journal of Thoravention–associated morbidity is not superseded by the risk of
sudden, potentially life-threatening, late-onset CHB. With
this rationale, in these patients with hemodynamically signif-
icant PMVSDs (ie, those with an unequivocal indication for
intervention), we believe that surgical closure remains the
treatment of choice.
Limitations
This is a single-center experience with small patient numbers
that is focused on the large PMVSDs that in our institution
would otherwise have been referred for surgical intervention.
Patient number was limited by the termination of this tech-
nique based on CHB incidence. It is not representative of
the entire PMVSD device experience, which includes many
older and larger patients and smaller defects. In the study
by Butera and coleagues,13 median weight was 26.5 kg,
mean pulmonary artery pressure was 16 6 5 mm Hg, and
37% of patients were older than 10 years. In this regard con-
troversy exists regarding the contemporary criteria for VSD
intervention because many of the patients in this series would
not have met the criteria for VSD intervention in our institu-
tion.27-30 Only one type of device was used, and it is conceiv-
able that alternative designs might be more favorable.
Conclusion
We sought to close significant PMVSDs in infants and small
children who would otherwise have required cardiac surgery.
Device architecture and sizing to avoid the conduction tissue
around the complex geometry of the PMVSD has significant
limitations. Despite excellent results for closure, there was
a high rate of CHB (22%). No risk factors for CHBwere iden-
tified. The late and insidious nature of the onset of CHB is
a critical caveat for device closure of these large defects.
Long-term follow-up is essential in patients who have had
these devices implanted.
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